Glucagon: FDA status and clinical evidence
Glucagon is approved by the FDA and is on the US market, first approved November 14, 1960, under 12 applications. 1516 studies are registered on ClinicalTrials.gov, reaching Phase 4. 8 unexpired patents are listed in the Orange Book.
FDA approval status
FDA review documents
Clinical evidence
By phase
Patents and generic availability
Molecular identity
76LA80IG2GHSQGTFTSDYSKYLDSRRAQDFVQWLMNTFrom the FDA Global Substance Registration System, the registry that assigns every substance the FDA tracks a unique identifier.
Frequently asked questions
Is Glucagon FDA-approved?
Yes. Glucagon holds FDA approval and is marketed in the US. Approval covers the specific uses, doses and forms on the FDA label, not every use it is sold or discussed for.
How much clinical research is there on Glucagon?
1516 studies are registered on ClinicalTrials.gov with Glucagon as an intervention, 793 of them completed. The highest phase reached is Phase 4. Registration counts research activity, not proven benefit.
What brand names is Glucagon sold under?
FDA records list BAQSIMI, GLUCAGEN, GLUCAGON, GVOKE HYPOPEN, GVOKE KIT, GVOKE PFS, GVOKE VIALDX. Brand availability changes over time, and some applications on file are marked discontinued.
Where does the information on this page come from?
Four FDA and NIH sources: Drugs@FDA for approval records, the FDA Orange Book for patents and exclusivity, the FDA Global Substance Registration System for molecular identity, and ClinicalTrials.gov for trial counts. Each is refreshed on a schedule and the date above shows the last refresh.
Sources: Drugs@FDA, FDA Orange Book, FDA Global Substance Registration System and ClinicalTrials.gov. Last refreshed 2026-10-16.